News & Updates

Once-daily treatment with baricitinib resulted in clinically meaningful improvements in hair regrowth on the scalp, eyebrows, and eyelashes among adolescent patients with severe alopecia areata (AA), according to the BRAVE-AA-PEDS trial presented at AAD 2025.

Repeated administration of low-dose lysergic acid diethylamide (LSD) in an outpatient setting is not necessarily better than placebo at reducing symptoms of attention-deficit/hyperactivity disorder (ADHD), according to the results of a phase IIA trial.

In adults with virologically suppressed HIV-1* infection, switching to a two-drug regimen of doravirine 100 mg and islatravir 0.25 mg (DOR/ISL) was noninferior to continuing bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) or other baseline antiretroviral therapy (bART) regimens in maintaining viral suppression at 48 weeks, according to two phase III trials presented at CROI 2025. 

Treatment with acoramidis results in a decrease in the composite of all-cause mortality or first cardiovascular-related hospitalization (CVH) in patients with transthyretin amyloid cardiomyopathy (ATTR-CM), reports a study.

The investigational anti–IL-23 monoclonal antibody QX004N appears to be well tolerated and have superior efficacy vs placebo in the treatment of patients with moderate to severe plaque psoriasis, according to a phase I study from China.

Complications following cataract surgery appear to be more frequent among patients with prior intravitreal injection (IVI) therapy than among those without, as shown in a retrospective study.